Abera Bioscience (ABERA) Q4 2024 earnings summary

Executive summary

• Achieved strong development in 2024, advancing as a leader in mucosal vaccines and securing over 35 MSEK in grants and strategic partnerships.

• Key preclinical results: pneumococcal vaccine Ab-01.12 showed 1000x efficacy over Prevnar 13 in mice; influenza candidate demonstrated full protection in animal models.

• Received major grants: 1 MSEK from Vinnova, 11 MSEK from CEPI, and continued UK Vaccine Network support for pandemic preparedness.

• Initiated collaborations with Orexo for nasal influenza vaccine powder formulation and expanded lab capacity in Sweden.

• Strengthened IP with EU patent approval for core platform technology.

Financial highlights

• Full-year 2024 revenue (mainly grants): 14,848 KSEK, up from 2,646 KSEK year-over-year.

• Net result for 2024: -1,100 KSEK, a significant improvement from -16,720 KSEK in 2023.

• Q4 2024 net result: 202 KSEK, compared to -2,419 KSEK in Q4 2023.

• Cash and bank at year-end: 6,090 KSEK (3,319 KSEK in 2023); equity: 8,656 KSEK (5,656 KSEK in 2023).

• Operating costs for 2024: -15,969 KSEK, down from -19,448 KSEK in 2023.

Outlook and guidance

• Financing secured for at least 12 months ahead, supported by grants from CEPI and UK Vaccine Network.

• Will not initiate GMP manufacturing or Phase 1 for Ab-01.12 until full funding is secured.

• Additional grant payments expected in 2025, tied to project milestones.

• Focus remains on cost-effective development and expanding the vaccine pipeline.